Clinical Trials /

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

NCT01548144

Description:

The goal of this clinical research study is to find the highest tolerable dose of the combination of Xalkori (crizotinib) either with Votrient (pazopanib) or Alimta (pemetrexed) or of the combination of 3 study drugs that can be given to patients with advanced cancer. The safety of these drug combinations will also be studied. Crizotinib is designed to block a protein called ALK, which is involved in cancer cell growth and survival. Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for tumor growth. This may prevent or slow the growth of cancer cells. Pemetrexed is designed to block proteins that may cause tumors to grow. This is an investigational study. Crizotinib is FDA approved and commercially available for the treatment of locally advanced or metastatic non-small cell lung cancer. Pazopanib is FDA approved and commercially available for treatment of advanced renal cell carcinoma. Pemetrexed is FDA approved and commercially available for the treatment of non-small cell lung cancer. The combination of crizotinib with pazopanib, crizotinib with pemetrexed, pazopanib with pemetrexed, and giving all 3 drugs together to patients with advanced cancer is investigational. Up to 364 patients will take part in this study. All will be enrolled at MD Anderson.

Related Conditions:
  • Cancer
Recruiting Status:

Active, not recruiting

Phase:

Phase 1

Trial Eligibility

Document

<span class="go-doc-concept go-doc-intervention">Pazopanib</span> or <span class="go-doc-concept go-doc-intervention">Pemetrexed</span> and <span class="go-doc-concept go-doc-intervention">Crizotinib</span> in Advanced Cancer

Title

  • Brief Title: Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
  • Official Title: A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies
  • Clinical Trial IDs

    NCT ID: NCT01548144

    ORG ID: 2011-1142

    NCI ID: NCI-2012-00324

    Trial Conditions

    Advanced Cancers

    Trial Interventions

    Drug Synonyms Arms
    Crizotinib (Xalkori) PF-02341066, Xalkori Crizotinib + Pazopanib - Group A, Crizotinib + Pemetrexed - Group B, Crizotinib + Pazopanib + Pemetrexed - Group D
    Pazopanib GW786034 Crizotinib + Pazopanib - Group A, Pazopanib + Pemetrexed - Group C, Crizotinib + Pazopanib + Pemetrexed - Group D
    Pemetrexed LY231514, Alimta, MTA, Multitargeted Antifolate, NSC-698037 Crizotinib + Pemetrexed - Group B, Pazopanib + Pemetrexed - Group C, Crizotinib + Pazopanib + Pemetrexed - Group D

    Trial Purpose

    The goal of this clinical research study is to find the highest tolerable dose of the
    combination of Xalkori (crizotinib) either with Votrient (pazopanib) or Alimta (pemetrexed)
    or of the combination of 3 study drugs that can be given to patients with advanced cancer.
    The safety of these drug combinations will also be studied.

    Crizotinib is designed to block a protein called ALK, which is involved in cancer cell
    growth and survival.

    Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for
    tumor growth. This may prevent or slow the growth of cancer cells.

    Pemetrexed is designed to block proteins that may cause tumors to grow.

    Detailed Description

    Study groups:

    Dose escalation:

    If you are found to be eligible to take part in this study, your doctor will decide if you
    will receive one of the following drug combinations:

    - If you are in Group A, you will receive crizotinib and pazopanib.

    - If you are in Group B, you will receive crizotinib and pemetrexed.

    - If you are in Group C, you will receive pazopanib and pemetrexed.

    - If you are in Group D, you will receive crizotinib, pazopanib, and pemetrexed.

    Once it is decided which combination you will receive, you will be assigned to a dose level
    based on when you join the study.

    Up to 8 dose levels of crizotinib with pazopanib will be tested. Up to 6 dose levels of
    crizotinib with pemetrexed will be tested. Up to 6 dose levels of pazopanib with pemetrexed
    will be tested. Up to 8 dose levels of pazopanib with pemetrexed and crizotinib will be
    tested. Up to 6 participants will be enrolled at each dose level.

    The first group of participants will receive the lowest dose level. Each new group will
    receive a higher dose than the group before it, if no intolerable side effects were seen.
    This will continue until the highest tolerable dose combination is found.

    Dose expansion:

    Once the highest tolerable dose of each study drug combination is found, up to 14 more
    participants may be enrolled to further study the safety of each combination of drugs at
    that dose.

    Study Drug Administration:

    Each study cycle is 21 days. Drugs should be taken and/or administered simultaneously. On
    days of pharmacokinetic testing (if you agree) you should take the drugs at least 1 hour
    before or 2 hours after a meal.

    If you are taking crizotinib, you will take it by mouth at the same time every day
    consistently either with or without food. It should be swallowed whole with a glass of
    water. You will take the drug every other day, 1 or 2 times a day. You will be told how
    often to take this drug.

    If you are taking pazopanib, you will take it by mouth at the same time every day with a
    glass of water. You should take it at least 1 hour before or 2 hours after a meal.

    If you receive pemetrexed:

    - You will receive it by vein on Day 1 of each cycle over about 10 minutes.

    - The day before your first dose of pemetrexed, you will start taking folic acid to help
    lower the risk of side effects. Although the study drug is designed to prevent the
    body from making folic acid that could help cancer grow and spread, some folic acid is
    needed to prevent side effects in non-cancerous tissue. You will take folic acid by
    mouth 1 time every day until at least 30 days after you received the last dose of
    pemetrexed.

    - The day before your first dose of pemetrexed, you will receive a vitamin B12 injection.
    You will receive an injection of Vitamin B12 about every 9 weeks after that. Vitamin
    B12 is given to help reduce the risks of side effects.

    - You will take dexamethasone by mouth 2 times a day on the day before, the day of, and
    the day after you receive pemetrexed.

    Study Visits:

    At every study visit, you will be asked about any other drugs or herbal supplements you are
    taking and about any side effects you may have.

    During Cycles 1 and 2, you will have weekly blood (about 1 tablespoon) collected for routine
    tests.

    During Week 1 of Cycles 2 and beyond:

    - Your medical history will be recorded, including any cancer symptoms.

    - You will have a physical exam, including measurement of your weight and vital signs.

    - Your performance status will be recorded.

    - Blood (about 1 tablespoon) and urine will be collected for routine tests.

    - If your doctor thinks it is needed, you will have an ECG to check your heart function.

    Every 6 weeks, or earlier if needed, blood (about 1 tablespoon) will be drawn for tumor
    marker testing.

    After about 6 weeks and then every 2-3 cycles after that, you will have a CT scan, x-ray,
    MRI scan, and/or PET scan to check the status of the disease. It may be done more often if
    your study doctor thinks it is needed.

    If you are able to become pregnant, you will have a blood (about 1 teaspoon) or urine
    pregnancy test every 2 cycles or at any time the study doctor thinks it is needed.

    Length of Study Participation:

    You may continue taking the study drugs for as long as the doctor thinks it is in your best
    interest. You will no longer be able to take the study drugs if the disease gets worse, if
    intolerable side effects occur, or if you are unable to follow study directions.

    Your participation on the study will be over once you have completed the end-of-dosing
    and/or follow-up visits.

    End-of-Dosing Visit:

    Within 30 days after your last dose of study drugs, you will have an end-of-study visit. If
    you are having side effects at the time of this visit, you may have follow-up for a longer
    period of time. At this visit, the following tests or procedures may be performed:

    - Your medical history will be recorded, including any cancer symptoms.

    - You will be asked if you have had any side effects.

    - You will have a physical exam, including measurement of your weight and vital signs.

    - Your performance status will be recorded.

    - Blood (about 1 tablespoon) and urine will be collected for routine tests.

    - Blood (about 1 tablespoon) will be drawn for tumor marker testing.

    - If the doctor thinks it is needed, you will have an x-ray, CT scan, MRI scan, and/or
    PET/CT scan to check the status of the disease.

    - If your doctor thinks it is needed, you will have an ECG to check your heart function.

    This is an investigational study. Crizotinib is FDA approved and commercially available for
    the treatment of locally advanced or metastatic non-small cell lung cancer. Pazopanib is FDA
    approved and commercially available for treatment of advanced renal cell carcinoma.
    Pemetrexed is FDA approved and commercially available for the treatment of non-small cell
    lung cancer.

    The combination of crizotinib with pazopanib, crizotinib with pemetrexed, pazopanib with
    pemetrexed, and giving all 3 drugs together to patients with advanced cancer is
    investigational.

    Up to 364 patients will take part in this study. All will be enrolled at MD Anderson.

    Trial Arms

    Name Type Description Interventions
    Crizotinib + Pazopanib - Group A Experimental Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug. Dose Expansion Group: MTD from Phase 1. Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle. Dose Expansion Group: MTD from Phase 1. Crizotinib (Xalkori), Pazopanib
    Crizotinib + Pemetrexed - Group B Experimental Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug. Dose Expansion Group: MTD from Phase 1. Starting dose for Pemetrexed: 200 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle. Dose Expansion Group: MTD from Phase 1. Crizotinib (Xalkori), Pemetrexed
    Pazopanib + Pemetrexed - Group C Experimental Starting dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle. Expansion group starting dose: MTD from Phase 1. Starting dose for Pemetrexed: 200 mg/m2 by vein on Day 1 of a 21 day cycle. Expansion group starting dose: MTD from Phase 1. Pazopanib, Pemetrexed
    Crizotinib + Pazopanib + Pemetrexed - Group D Experimental Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug. Dose Expansion Group: MTD from Phase 1. Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle. Dose Expansion Group: MTD from Phase 1. Starting dose for Pemetrexed: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle. Dose Expansion Group: MTD from Phase 1. Crizotinib (Xalkori), Pazopanib, Pemetrexed

    Eligibility Criteria

    Inclusion Criteria:

    1. Patients with advanced cancer, either refractory to standard therapy or for which no
    effective standard therapy that increases survival for at least 3 months is
    available.

    2. Patients must have measurable or evaluable disease, as defined by RECIST 1.1.

    3. Women of child-bearing potential and men must agree to use adequate contraception.

    4. ECOG performance status of 0 to 2.

    5. Adequate organ functions: (Crizotinib plus Pazopanib arm A): Neutrophils > 1000/uL;
    Platelets 75,000/uL; Total bilirubin < or= 2 x ULN (upper limit of normal); ALT <
    or = 2.5 x ULN or < o r= 5 x ULN if liver metastases persist; Serum creatinine < 2 x
    ULN (Crizotinib plus Pemetrexed arm B, Pazopanib plus Pemetrexed arm C, Crizotinib
    plus Pazopanib plus Pemetrexed arm D) Neutrophils > 1500/uL; Platelets > or =
    100,000/uL; Total bilirubin < or = 2 x ULN (upper limit of normal); ALT < or = 2.5 x
    ULN or < or = 5 x ULN if liver metastases persist; Calculated GFR > 45 mL/min.

    6. Creatinine Clearance: The standard Cockcroft and Gault formula must be used to
    calculate CrCl for enrollment or dosing. Also include in the pre-treatment or
    baseline text portion of the protocol, the 'On Study Evaluations or During Treatment'
    for every Pemetrexed treatment day, and also capture in the study Schedule of Events.
    No dosage adjustment is needed in patients with creatinine clearance > 45 mL/min.
    Insufficient numbers of patients have been studied with creatinine clearance <45
    mL/min to give a dose recommendation. Therefore, Pemetrexed should not be
    administered to patients whose creatinine clearance is <45 mL/min.

    7. For pemetrexed arms: The ability to interrupt NSAIDs 2 days before (5 days for
    long-acting NSAIDs), the day of, and 2 days following administration of Pemetrexed.

    8. The ability to take folic acid, Vitamin B12, and dexamethasone according to protocol
    for all pemetrexed arms.

    9. Expansion cohort only for arms containing crizotinib: arm A (Crizotinib plus
    Pazopanib) and arm B (Crizotinib plus Pemetrexed) and arm D (Crizotinib plus
    Pazopanib Plus Pemetrexed) but not arm C (Pazopanib plus Pemetrexed). Patients must
    have ALK abnormality including: translocation, ALK amplification, mutation and
    overexpression as determined by FISH, IHC, qPCR, qRT-PCR, array Comparative Genomic
    Hybridization or direct sequencing (aCGH). Or patients must have a c-Met abnormality;
    either c-Met amplification or c-Met mutation or patients must have the ROS1
    translocation as determined by FISH.

    10. Additional eligibility criteria for pediatric subjects: Patient must be > 12 months
    and </= 21 years of age at the time of study enrollment.

    11. Additional eligibility criteria for pediatric subjects: Patient is able to swallow
    tablets and capsules.

    12. Additional eligibility criteria for pediatric subjects: Patient's body surface area
    is >/= 0.84 m^2.

    Exclusion Criteria:

    1. Patient receiving any concurrent chemotherapy.

    2. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
    infection requiring intravenous antibiotics.

    3. Symptomatic congestive heart failure (NYHA Class III or IV), unstable angina pectoris
    or congenital long QT syndrome.

    4. Medical and/or psychiatric problems of sufficient severity to limit full compliance
    with the study or expose patients to undue risk.

    5. Known anaphylactic or severe hypersensitivity to study drugs or their analogs.

    6. Patient has failed to recover from any prior surgery within 4 weeks of study entry.

    7. Patient is pregnant or lactating.

    8. Patient has had any treatment specific for tumor control within 3 weeks of dosing
    with investigational drugs and cytotoxic agents, or within 2 weeks of cytotoxic agent
    given weekly, or within 6 weeks of nitrosoureas or mitomycin C, or within 5
    half-lives of biological targeted agents with half-lives and pharmacodynamic effects
    lasting less than 5 days (that includes, but is not limited to, erlotinib, sorafenib,
    sunitinib, bortezomib, and other similar agents).

    9. Patient has any signs of intestinal obstruction.

    10. Patient is not able to swallow oral medication.

    11. Patients receiving whole brain radiation within 14 days prior to the first dose of
    study drugs will be excluded. NOTE: Patients receiving palliative radiation (other
    than whole brain) before or during treatment may still be eligible as long as there
    are evaluable lesions that are not being irradiated.

    12. Pemetrexed arms only: Presence of third space fluid which cannot be controlled by
    drainage.

    13. Additional Exclusions for the 3 pazopanib containing arms (Crizotinib plus Pazopanib)
    and (Pazopanib plus Pemetrexed) and (Crizotinib plus Pazopanib plus Pemetrexed). 1.
    History of stroke or transient ischemic attack within 6 months prior to study
    enrollment. 2. History of abdominal fistula, gastrointestinal perforation, or
    intra-abdominal abscess within 6 months prior to study enrollment. 3. Urine for
    proteinuria > or = 2+ (patients discovered to have > or = 2+ proteinuria on
    urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate
    < or = 1g of protein in 24 hours to be eligible).

    Minimum Eligible Age: N/A

    Maximum Eligible Age: N/A

    Eligible Gender: Both

    Primary Outcome Measures

    Maximum Tolerated Dose (MTD) of Crizotinib and Pazopanib

    Secondary Outcome Measures

    Trial Keywords

    Advanced Cancers

    Advanced Malignancies

    Crizotinib

    PF-02341066

    Pazopanib

    Gw786034

    Pemetrexed

    LY231514

    Alimta

    MTA

    Multitargeted Antifolate

    NSC-698037